Last updated: May 11, 2026
RYTHMOL SR is an extended-release formulation of propafenone. No current, verifiable clinical-trials “update” through 2026 or drug-specific FDA commercial milestone dataset is provided in the input. A complete, citation-grade update and projection therefore cannot be produced.
What clinical trials are underway for RYTHMOL SR (propafenone ER) in 2025–2026?
No verifiable, drug-specific clinical trial record update is available in the provided information set. Without an auditable trial registry extract or publication list, a factual “what’s underway now” update for RYTHMOL SR cannot be compiled.
Which trial phases would matter for an ER antiarrhythmic label expansion?
Label expansions for antiarrhythmics typically run through Phase 2–3 and seek endpoints tied to arrhythmia suppression, safety/tolerability, and QT/QRS metrics. A factual mapping to RYTHMOL SR requires trial identifiers, which are not provided.
What does RYTHMOL SR’s market look like today, and who buys it?
No market sizing inputs are provided (sales, prescriptions, payer mix, channel, or geography). A market analysis that meets a litigation-grade standard requires audited or at least properly sourced datasets.
Competitive landscape: how does propafenone ER compare vs immediate-release propafenone and other antiarrhythmics?
RYTHMOL SR competes in the antiarrhythmic category, where treatment patterns often favor:
- immediate-release propafenone for shorter dosing intervals
- class IC alternatives
- other class therapies depending on patient and guideline pathways
A quantified comparison requires claims and formulary data not included in the input.
What share does RYTHMOL SR have versus other propafenone products?
No data is provided to compute or estimate share.
When does RYTHMOL SR lose exclusivity in the US?
No Orange Book exclusivity dataset, listed patents, or expiration dates are provided. Without Orange Book listings and associated regulatory exclusivity codes, exclusivity loss timing cannot be stated.
How do patent expiration and 180-day exclusivity risks affect generics for propafenone ER?
That risk analysis requires:
- specific Orange Book patent numbers with expiration dates
- any unexpired patents covering ER formulations, methods of use, or polymorphs
- any Paragraph IV litigation outcomes and 180-day triggers
No such inputs are provided.
What is the Orange Book status of RYTHMOL SR (propafenone ER)?
No Orange Book listing data is provided in the input. A status page typically requires listed NDA, patent numbers, expiration dates, and exclusivity.
Which patent types usually cover extended-release antiarrhythmics?
Extended-release antiarrhythmic products often have claim coverage for:
- controlled-release matrix or coating systems
- specific dissolution profiles or release kinetics
- formulation exemplars
- use claims tied to arrhythmia indications
A fact-based RYTHMOL SR estate map is not possible without the Orange Book record.
How strong is the patent estate for RYTHMOL SR and what generic entry barriers exist?
No patent estate is provided. A “strength” scoring model needs the patent set size, remaining term, claim scope, and litigation history.
What patent litigation affects propafenone ER generics?
No litigation docket or case identifiers are included.
What generic launch scenarios could challenge RYTHMOL SR?
Generic entry timing depends on:
- remaining Orange Book exclusivities and patent expirations
- Paragraph IV filings and settlement terms
- formulation-specific patent barriers
No such data is available in the input, so launch timelines cannot be produced.
What regulatory pathway milestones would govern RYTHMOL SR supply and approvals?
A regulatory milestone forecast requires FDA review outcomes, supplement history, and any recent approval or manufacturing changes. None are provided.
Does RYTHMOL SR have any labeling or formulation changes affecting commercial outlook?
No label-change history is provided.
Key Takeaways
- A clinical-trials update for RYTHMOL SR (2025–2026) cannot be compiled from the provided input without trial identifiers or sourced registry data.
- A market analysis and projection cannot be quantified without sales, prescriptions, formulary, and geography datasets.
- Exclusivity timing, Orange Book status, patent estate strength, Paragraph IV risk, and generic launch scenarios cannot be stated without Orange Book patent listings and regulatory exclusivity records.
FAQs
- What active ingredient and dosage form is RYTHMOL SR, and what dosing schedule is used?
- Are there any FDA-approved generic extended-release propafenone products available, and when were they approved?
- Which antiarrhythmics are most commonly substituted for propafenone ER at the formulary level?
- What endpoints are typical for antiarrhythmic clinical trials supporting ER formulation labels?
- How do Orange Book patent expirations usually translate into generic launch timing for extended-release cardiovascular drugs?
References
- FDA Orange Book (Drug Products); Orange Book data not provided in the input.
- ClinicalTrials.gov; trial records not provided in the input.
- FDA labeling and prescribing information for RYTHMOL SR; not provided in the input.
